Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Adsorbed Cell-free DPT Vaccine (Tdcp) in People Aged 6 Years and Above
NCT06056050Phase 1Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Dec 2023
- Primary completion
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed in diphtheria, Tetanus and pertussis (6 arms), sponsored by CanSino Biologics Inc. Primary endpoint: Incidence of adverse reactions 0-30 days after vaccination. Started Dec 2023; status: completed.
02
Drugs
Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on NCT06056050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056050.